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Preface 
 
 
Outbreaks of contagious animal diseases such as Classical Swine Fever have 
detrimental effects on the livestock sector in an affected country as well as on 
society at large. The development of antiviral agents to control these epidemics 
can reduce the consequences of such outbreaks. The economic impact of 
applying these antiviral agents is until now unknown. In this report these 
consequences are investigated. This report is the result of a close cooperation 
between two institutes of Wageningen UR: LEI and CVI. It shows that an effective 
multi-disciplinary approach leads to better insights into complex problems. 
 We trust that the results of this research will assist policy makers and 
producers of antiviral agents in choosing the optimal strategy in the case of an 
outbreak of Classical Swine Fever. 
 
 
 
 
 
L.C. van Staalduinen MSc 
Managing Director LEI Wageningen UR 
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Summary 
 
 
S.1 Key findings 
 
The maximum price of antiviral agents to control Classical Swine Fever (CSF) 
epidemics has been determined. The price tolerance per dose (including 
application costs) amounts to approximately €10 if only treatment with antiviral 
agents in a 2-km radius around infected premises is considered (culling in a 1-km 
radius is applied as the reference eradication strategy). The price tolerance is 
about €7 per dose if a combination of vaccination (of finishers and piglets) and 
treatment with antiviral agents (of sows) in a 2-km radius around infected 
premises is considered (a 2-km emergency vaccination of finishers and piglets 
is taken as the reference eradication strategy). A price per dose below these 
prices makes a control strategy with treatment of antiviral agents the 
economically preferred eradication strategy in the case of a CSF outbreak in a 
densely populated livestock area in the Netherlands. See Chapter 5 
 
Table S.1 Maximum price per dose (euro) 
Eradication strategy a) vac1_av1 vac2_av2 av1 av2 
EU 921 581 67 49 
cul1 158 116 10 10 
vac1_EU 15 29 -1 3 
vac2_EU -22 7 -4 1 
a) EU measures (EU) always apply; additionally, animals are either pre-emptively culled (cul), emergency vaccinated 
(vac), treated with antiviral agents (av) or vaccinated and treated (vac_av) depending on herd type. The number 
denotes the control radius in km around detected farms. 
 
 
S.2 Complementary findings 
 
- The maximum price per dose depends on the eradication strategy applied 
and the chosen reference strategy. 
- The maximum price per dose depends only to a limited extent on the size of 
an outbreak. 
- The maximum price per dose will be higher when export losses, ripple effects, 
spill-over effects and/or enforcement costs are also accounted for. See 
paragraph 3.2 
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S.3 Method 
 
- Based on the results of an epidemiological simulation study, a number of 
strategies were evaluated on their economic merits. Strategies focused on 
the effects of using antiviral agents. For this a partial budgeting approach 
was used. See paragraph 2.3 
- Application of antiviral agents during outbreaks of epidemic livestock diseases 
like CSF is a potential tool as a complementing eradication strategy in the 
case of an outbreak of CSF. Antiviral agents provide instantaneous protection 
without culling the susceptible animal, and do not induce an anti-CSF-virus 
antibody response, facilitating serological testing to regain the CSF-free 
status. See paragraph 1.1 
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Samenvatting 
 
 
S.1 Belangrijkste uitkomsten 
 
Er is een maximumprijs vastgesteld voor antivirale middelen die worden gebruikt 
voor het bestrijden van epidemieën van klassieke varkenspest. De prijstolerantie 
per dosis (inclusief toedieningskosten) bedraagt circa € 10 als een behandeling 
met antivirale middelen wordt overwogen in een straal van 2 km rond het 
besmette pand (het ruimen van varkens in een straal van 1 km wordt toegepast 
als de referentiestrategie). De prijstolerantie is circa € 7 per dosis als een 
combinatie van vaccinatie (van slachtvarkens en biggen) en behandeling met 
antivirale middelen (van zeugen) wordt overwogen in een straal van 2 km rond 
het besmette pand (noodvaccinatie van slachtvarkens en biggen in een straal 
van 2 km wordt toegepast als de referentiestrategie). Een prijs per dosis die 
lager is dan deze bedragen maakt een strategie op basis van behandeling met 
antivirale middelen de economisch meest aantrekkelijke uitroeiingsstrategie in 
het geval van een uitbraak van de klassieke varkenspest in een dichtbevolkt 
veehouderijgebied in Nederland. 
 
Tabel S.1 Maximumprijs per dosis (euro) 
Uitroeiingsstrategie a) vac1_av1 vac2_av2 av1 av2 
EU 921 581 67 49 
Ger1 158 116 10 10 
vac1_EU 15 29 -1 3 
vac2_EU -22 7 -4 1 
a) EU-maatregelen (EU) zijn altijd van toepassing; daarnaast worden dieren preventief geruimd (cul), krijgen ze een 
noodvaccinatie (vac), worden ze behandeld met antivirale middelen (av) of worden ze gevaccineerd en behandeld 
(vac_av), afhankelijk van de besmettingshaard. Het getal is de straal in km rond de gedetecteerde bedrijven 
waarbinnen de ziekte wordt bestreden. 
 
 
S.2 Overige uitkomsten 
 
- De maximumprijs per dosis is afhankelijk van de toegepaste uitroeiings-
strategie en de gekozen referentiestrategie. 
- De maximumprijs per dosis is slechts in beperkte mate afhankelijk van de 
omvang van een uitbraak. 
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- De maximumprijs per dosis zal hoger zijn wanneer er tevens rekening wordt 
gehouden met exportverliezen, verspreidingseffecten, spill-overeffecten 
en/of handhavingskosten.  
 
 
S.3 Methode 
 
- Op basis van de resultaten van een epidemiologische simulatiestudie is 
een aantal strategieën beoordeeld op de economische verdiensten. De 
strategieën waren gericht op de effecten van het gebruik van antivirale 
middelen. Hiervoor werd een 'partial budgeting'-aanpak gebruikt.  
- De toepassing van antivirale middelen bij een uitbraak van epidemische 
veeziekten als de klassieke varkenspest kan dienen als een aanvullende 
uitroeiingsstrategie in geval van een uitbraak van klassieke varkenspest. 
Antivirale middelen bieden direct bescherming en zorgen ervoor dat het 
dier niet hoeft te worden geruimd. Bovendien maakt het dier bij gebruik van 
deze middelen geen antilichamen aan tegen de klassieke varkenspest, zodat 
door middel van serologische tests de status varkenspestvrij kan worden 
verkregen.  
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1 Setting the scene 
 
 
1.1 Introduction 
 
Epidemic livestock diseases like Classical Swine Fever (CSF) present a threat 
to the productivity of the livestock sector and can have substantial effects on 
national economies. Therefore a rapid detection and eradication is of utmost 
importance. In the case of an outbreak of CSF, the Competent Authorities apply 
control measures to eliminate the infection from its territory and to avoid spread 
to other member states (MSs). 
 Given the importance of this epidemic livestock disease for MSs and EU 
economy the EU agreed upon a minimal set of measures to be applied in the 
case of an outbreak of CSF (Council Directive 2001/89/EC). Especially in MSs 
with a large, concentrated and intensive livestock sector the EU minimum 
measures do not lead to a swift and efficient containment of the epidemic and 
additional measures need to be applied. These measures can consist of 
preventive culling in a circle around infected farms, the application of movement 
restrictions and/or vaccination in an area around infected farms. These specific 
additional control measures can only be applied after approval by the EU 
Commission. 
 Control measures are associated with costs. Detection and culling of 
infected farms, preventive culling of high risk farms, movement restrictions 
to prevent further spread of infection, vaccination as well as other additional 
preventive measures are accompanied with substantial cost for the government 
as well as the livestock production chain. Besides these direct costs, costs 
related to export bans and (temporary) loss of export markets within and 
outside the EU occur. For exporting MSs like the Netherlands, Belgium and 
Denmark these export losses may even be larger than the direct costs of an 
outbreak. In Appendix 1 the present control measures as described in the 
Dutch Contingency Plan CSF are summarised (in Dutch). 
 Application of antiviral agents during outbreaks of epidemic livestock 
diseases like CSF is a further potential tool in the pallet of additional measures. 
Antiviral agents provide instantaneous protection without culling the animal, and 
do not induce an anti-CSF-virus antibody response, facilitating serological testing 
to regain the CSF-free status. They can be used to protect sows that are not 
vaccinated in the current Dutch contingency plan strategy, or used as an 
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alternative control measure where all animals are treated with antiviral agents 
(i.e., sows, piglets and finishing pigs). 
 In a previous study the use of antiviral agents as an alternative or additional 
strategy to control CSF epidemics was reported in terms of epidemiological 
effects (Backer, 2011). A number of the evaluated strategies in the 
epidemiological study were used to evaluate the economic effects of using 
antiviral agents to contain CSF outbreaks. The results of this economic study 
are presented below. 
 
Economic effects of an outbreak of CSF 
When evaluating the costs of an epidemic of a contagious disease like CSF, different 
components can be distinguished: 
- Direct costs related to the control of the epidemic. 
These include the costs for the infrastructure for the control of the epidemic, the costs 
associated with culling and destroying of infected and contact animals, the costs 
associated with destruction of feed on detected farms, the compensation and vaccination 
costs.  
- Enforcement costs. 
Costs related to the enforcement of movement restrictions (police and other inspection 
services). 
- Costs related to trade restrictions. 
Due to an epidemic the national and international market access for animals of susceptible 
species and their products is restricted. An epidemic of CSF will result in trade restrictions 
that are mostly related to the epidemic per se and do not depend on the specific 
characteristics of the control strategy chosen. After the last outbreak it takes time until all 
the restrictions in trade are lifted and the situation from before the epidemic is restored. 
For example after an outbreak of CSF in a country, trade with third countries of pigs and 
pork products is restricted for 6 months. For trade within the EU, the Commission can 
decide that this period can be shorter depending on the measures taken by the MS. 
- Ripple effects. 
The effects from outbreaks of CSF that are felt upstream and downstream along the 
livestock value chain: breeding, feed production, input supply, slaughter, processing, 
final sale and consumption. 
- Spill-over effects. 
Spill-over effects are effects of an outbreak outside the affected livestock production chain. 
These are for example the effects from outbreaks of CSF on tourism and other services. 
Since other than typical agricultural production is becoming more important for the rural 
economy, these spill-over effects are likely to become a large part of the total epidemic costs. 
 
 The duration of the trade restrictions has a large effect on the economic consequences 
for an infected country. For a country like the Netherlands, which depends to a large extent 
on export of pigs and pig meat, the duration of a trade restriction from infected areas within 
and outside the EU determines these economic effects for a large part. 
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1.2 Objective of the research 
 
The following research questions were answered to obtain an insight into the 
economic aspects of the application of antiviral agents in the control of an 
outbreak of CSF in a densely populated livestock area (DPLA) in the Netherlands: 
1. What are the economic differences between the eradication strategies? 
2. What is the 'price tolerance' of the application of antiviral agents? 
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2 Material and Methods 
 
 
2.1 Epidemiological data 
 
The epidemiological data as presented in Backer (report 2011, publication 
in preparation) were used as input for the economic calculations. In total 
8 strategies were analysed. 
 
Control strategies 
 
Table 2.1 Overview of control strategies evaluated in the economic 
evaluation a) 
Control strategy Animal type 
Finishers Piglets Sows 
EU EU EU EU 
cul1 cul1 cul1 cul1 
vac1_EU vac1 vac1 EU 
vac1 _av1 vac1 vac1 av1 
vac2 _EU vac2 vac2 EU 
vac2 _av2 vac2 vac2 av2 
av1 av1 av1 av1 
av2 av2 av2 av2 
a) EU measures (EU) always apply; additionally, animals are either pre-emptively culled (cul), emergency vaccinated 
(vac), treated with antiviral agents (av) or vaccinated and treated (vac_av) depending on herd type. The number 
denotes the control radius in km around detected farms. 
 
The benchmark strategies 
EU: The EU demands a minimal control strategy, as required by Council 
Directive 2001/89/EC. All animals on infected detected farms are culled, 
transport is regulated in protection and surveillance zones, and dangerous 
contacts are actively screened and traced. 
 
 15 
 The measures of the EU strategy always apply; additional measures are 
taken in the following control strategies: 
 
cul1: Additional pre-emptive depopulation in a 1-km radius around infected 
premises is the preferred strategy of the EU in a DPLA. 
 
vac1_EU: Emergency vaccination of finishing pigs and piglets in a 1-km radius 
around infected premises instead of preventive culling. Sows are excluded from 
vaccination to minimise the risk of persistently infected piglets. 
 
vac2_EU: Emergency vaccination of finishing pigs and piglets in 2 km around 
infected premises instead of preventive culling. This is the preferred strategy in 
The Netherlands. Sows are excluded from vaccination to minimise the risk of 
persistently infected piglets. 
 
Strategies that include treatment with antiviral agents 
In the case of treatment with antiviral agents the following assumptions are 
made: 
- If sows are treated, the suckling piglets are assumed to be protected via 
the milk. 
- Antiviral treatment will take place for the duration of 15 days but this period 
can become longer when another infected herd is newly detected within the 
control radius. However, the maximally allowable treatment duration is set at 
30 days. 
 
The following strategies were evaluated: 
 
av1: EU control measures always apply. On top of this, all susceptible animals 
in a control radius of 1 km are treated with antiviral agents. 
 
av2: As av1, but now all animals are treated in a radius of 2 km. 
 
vac1_av1: EU control measures always apply. Emergency vaccination of 
finishers and piglets in a 1-km radius around infected premises. Sows are 
excluded from vaccination to minimise the risk of persistently infected piglets. 
Non-vaccinated sows are treated with antiviral agents in a 1-km radius around 
infected premises. 
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vac2_av2: As vac1_av1, but with emergency vaccination of finishers and piglets 
in a 2-km radius around infected premises and non-vaccinated sows are treated 
with antiviral agents in a radius of 2 km around infected premises. 
 
 A summary of the epidemiological data is provided in Table 2.2 (originating 
from the calculations of Backer in 2011). 
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2.2 Economic data used 
 
To evaluate the economic consequences of the different control strategies 
an existing economic model was used (Backer et al., 2009). Since the main 
objective of this research is to compare the effects of different control strategies, 
only those costs and benefits that were expected to differ substantially between 
the evaluated alternatives are included. The costs that are included in the 
calculations are in Table 2.3. In the next section the costs that are included or 
excluded in the model are addressed. Also, the assumed values are given. 
 Price data of 2012 were used. In case they are unknown (e.g. because 
some costs can only be determined after an outbreak) they are based on 
historical data indexed for a price level of 2012. Price indexes of CBS 
(www.cbs.nl) were used. 
 
Table 2.3 Economic input parameters used in the economic evaluation 
(2012 price level) 
Screening and sampling Vaccination costs 
Taking samples 
as suspect 
298,684 €/infected 
farm 
Sows 0.00 €/animal 
Execution of 
screening 
244,444 €/infected 
farm 
Piglets 2.26 €/animal 
Total screening 
and sampling 
543,128 €/infected 
farm 
Fattening pigs 2.26 €/animal 
Taxation and 
materials per 
culled farm  
7,180 €/culled 
farm 
Value of compensated animals including 
feed 
Destruction (transport included) Sows 467 €/animal 
Sows 109 €/animal Piglets 45 €/animal 
Piglets 0.00 €/animal Fattening pigs 106 €/animal 
Fattening pigs 15 €/animal Empty farm buildings during outbreak 
Clearing and disinfection  Sows 0.99 €/animal/day 
Sows 502 €/animal Piglets  0.00 €/animal/day 
Piglets 0.00 €/animal Fattening pigs 0.20 €/animal/day 
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Table 2.3 Economic input parameters used in the economic evaluation 
(2012 price level) (continued) 
Screening and sampling Vaccination costs 
Fattening pigs  188 €/animal Costs of transportation 
prohibition of non-
infected farms with 
fattening pigs, first 
6 weeks 
11.01 €/animal 
Repopulation costs  
Sows 181 €/animal    
Piglets  0.00 €/animal    
Fattening pigs 12 €/animal    
 
- Screening and sampling 
These are costs related to screening and sampling, as well as costs of crisis 
centres, tracking and tracing, clinical examination and clinical inspection, 
based on the total cost of the 2001 epidemic in the Netherlands (Huirne 
et al., 2002). 
 
- Costs of clearing and disinfection 
The labour costs of culling of animals and disinfection of farms, based on 
Huirne et al. (2002). 
 
- Compensation for culled pig herds 
The costs of culled animals are the number of culled animals times the value 
of each animal. The costs of destructed feed are the number of culled 
animals times the average value per animal of the stock of feed present on 
the farm. The value of culled animals was based on value tables that are 
regularly updated.1 Values were calculated as averages over all ages, since 
the stage in the production cycle is unknown for individual farms. 
 
                                                 
1 To improve the process of valuation of animals culled during an epidemic the Dutch Competent Authorities 
and the livestock sector agreed upon a method for valuation ('Waardetabellen'). Based on this procedure an 
annually updated value table prepared by LEI for different types of animals has been created. 
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- Costs of empty housing 
These are costs of empty housing between the moment of culling and the 
moment of repopulation after the epidemic and a 30-day period after the last 
detection. 
 
- Costs of repopulation 
The culled farms incur costs after repopulation because of suboptimal 
utilisation of their capacity. 
 
- Costs of transportation prohibition of non-infected farms and welfare 
slaughter 
The costs were calculated of non-infected farms in an area with transport 
prohibition for a 6-week period because of missed returns. Only these costs 
were calculated for finisher pigs. It is assumed that sows will not have 
welfare problems and will not lose value during a transport prohibition. 
 
- Costs of empty houses and repopulation of non-infected farms in infected 
compartments 
Pigs are sufficiently available in the Netherlands in the area with movement 
restrictions to prevent empty housing. 
 
- Costs of vaccinating 
The labour costs of vaccination of animals and the vaccine costs. 
 
- Value loss of vaccinated animals 
The value loss of vaccinated animals is the number of vaccinated animals 
times the average value loss of each animal if sold on the Dutch market. The 
estimates for the value loss of products from vaccinated pigs were based 
on previous research by Van Asseldonk and Bergevoet (2011, unpublished 
data). 
 
- Costs of logistic processing of vaccinated animals 
During the epidemic and the 30-day period after last detection, vaccinated 
pigs are processed similarly to non-vaccinated animals. Vaccinated animals 
that are still alive after this period have to be logistically slaughtered and 
corresponding costs were calculated. Vaccinated hobby animals were not 
slaughtered and incurred no additional costs. 
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- Costs of antiviral drugs 
Since determination of the price tolerance of the antiviral drugs (and their 
application) is the objective of the present study, no price for the antiviral agents 
(and their application) is included in the initial calculations. Also, it assumed that 
there are no restrictive measures associated with respect to the withdrawal 
period1 and market access that could hamper the sale of products originating 
from animals treated with these agents. 
 
Excluded from the calculation 
- Enforcement costs: costs of police involvement and other control agencies 
in the enforcement of movement restrictions. A sensitivity analysis is 
conducted based on assumptions presented in Appendix B. Enforcement 
costs are substantial. There are two issues with respect to these 
enforcement costs: 1) They are not eligible for reimbursement under the EU 
Veterinary Fund and 2) They are difficult to estimate, since they depend on 
the location of the outbreaks, the enforcement deemed necessary by the 
competent authorities and the expected cooperation of farmers in the 
affected areas. 
- Ripple effects: costs that occur in the pig value chain. 
- Spill-over effects: costs that can occur during an epidemic of CSF in 
branches not primarily affected such as horses, poultry, sheep, pigs and 
cattle farming and arable land and the costs of non-agricultural industry as 
tourism are also not analysed (i.e.). 
- Export market losses were excluded in the economic analysis since they 
strongly depend on the duration of the outbreak. 
- In this evaluation only the economic effects of the occurrence of the first 
outbreak in a Densely Populated Livestock Area (DPLA) are evaluated; the 
effects of a first outbreak in a Sparsely Populated Livestock Area (SPPA) are 
not evaluated. 
 
                                                 
1 The withdrawal period is the period between the last application of the antiviral drugs and the moment the 
animal can be slaughtered and the products are safe for human consumption. After the last outbreak it will 
take at least 42 days before movement restrictions are lifted and animals can be slaughtered. However, in 
the case of a long duration of an outbreak, animal welfare problems on farms affected by movement re-
strictions might occur. In such cases, farmers can be allowed to slaughter animals in dedicated slaughter 
houses under strict restrictions. To enable this welfare slaughter on treated farms, the withdrawal time de-
termines the minimal time after treatment this welfare slaughter can occur. 
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2.3 Methods used for the economic analysis 
 
The method of economic evaluation comprised three steps. 
1. Calculating economic differences between the different eradication 
strategies. 
2. The total costs of the evaluated strategies were pairwise compared and 
presented in a matrix structure. 
3. Determining the price tolerance. 
 
 The 'price tolerance' of antiviral agents is the price level per dose and their 
application at which two strategies are indifferent (i.e. with anti-viral agents 
compared with a reference strategy). Two reference strategies were investigated, 
namely with and without vaccination as part of the eradication strategy. 
 In the evaluated strategies the number of 'demanded' doses depends on the 
strategy chosen but also to a large extent on the evolvement of the epidemic 
under a given control strategy. Besides the price tolerance based on mean 
values, we also explore if the size of an outbreak and the number of doses of 
antiviral agents used have an impact on the maximum price. For the situation 
without and with vaccination the outbreaks were ranked. The maximum price 
per dose was determined per iteration by the using the following formula: 
 
 
Price int t= (Cost strategy- av int, t - Cost strategy+ av int, t)/ ( # doses int, t) 
 
 
 In which 'Cost strategy- av int, t ' are the total costs for the t
th iteration in which 
no antiviral agents were applied and 'Cost strategy+ av int, t' are the total costs 
for the tth iteration with application of antiviral agents, while '# doses int, t' are the 
number of doses needed for the tth iteration. 
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3 Results 
 
 
In the following paragraphs a number of tables and graphs with summarised 
results are presented. The numbers in italics in the tables are discussed in the 
text. In the strategies were antiviral agents are applied the results are exclusive 
the costs (of application) of the antiviral agents. 
 
 
3.1 Total costs and differences between control strategies 
 
In Table 3.1 the control costs are presented. The distribution of the total costs 
of the different control strategies is given in Figure 3.1 to Figure 3.3. Unless 
mentioned otherwise, the main text presents results of the variant excluding 
enforcement costs, which are presented in Appendix 3). 
 
Table 3.1 Costs of different control strategies in the case of an outbreak 
of CSF in a DPLA in the Netherlands, in million euros 
(excluding enforcement costs) 
 Total costs 
Mean  ( 5% 95% ) 
EU 692 114 1204 
cul1 185 70 356 
vac1_EU 90 40 158 
vac1_av1 a) 80 37 142 
vac2_EU 65 34 107 
vac2_av2 a) 58 31 94 
av1 a) 98 35 234 
av2 a) 53 26 95 
a) The cost of the antiviral agents and their application are not included in the calculations. 
 
 The total costs (excluding enforcement costs) differ substantially between 
the evaluated strategies (Table 3.1 and Figure 3.1). The EU strategy is the most 
expensive strategy (average of €692m per outbreak). The other strategies have 
substantially lower average costs. Strategy vac2_av2 has the lowest average 
costs (€58m). Large differences occur in possible outcomes between iterations 
(Figure 3.1). Costs gradually increase with increasing percentiles. Only at higher 
  
24 
percentile values (>95% percentile) costs rise steeply. The EU strategy has the 
highest costs at each percentile value followed by cul1. 
 Note that the control costs are the largest part of the total costs of the 
outbreak. In the situation enforcement costs excluded, the proportion of the 
costs borne by farmers amounts to 21% for cul1 and 47% for vac2_av2. In the 
situation where the enforcement costs are included, the fraction of the costs 
borne by the farmers varies between 13% for av1 and 26% for vac2_EU. 
 
Figure 3.1 Distribution of outcomes of the simulations a)  
 
a) The x axis gives the percentile and the y axis gives total costs in million euros. 
 
 The difference in total costs between the different control strategies is given 
in a cross table (Table 3.2). The average total costs for example of the EU 
strategy are €507m higher than for the cul1 strategy. 
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Table 3.2 Differences in mean total costs of different control strategies in 
the case of an outbreak of CSF in a DPLA in the Netherlands, 
in million euros (excluding enforcement costs) 
 EU cul1 vac1_EU vac1_av1 vac2_EU vac2_av2 av1 av2 
EU         
cul1 -507         
vac1_EU -602  -95        
vac1_av1 -612  -105  -10       
vac2_EU -626  -119  -25  -14      
vac2_av2 -633  -127  -32  -22  -7     
av1 -594  -87  8  18  32  40    
av2 -638  -132  -37  -27  -12  -5  -45   
 
 The EU strategy is likely to result in a very large, long-lasting epidemic, so it 
is not considered as a realistic option. To evaluate the potential benefits of a 
treatment with antiviral agents (excluding their costs), two scenarios are 
compared: 
1. a scenario in which vaccination is not considered as a policy option and cul1 
is the reference strategy for comparison (Figure 3.2); and  
2. a scenario in which vaccination is considered as a viable policy option and 
vac1_EU/va2_EU are the reference strategies for comparison (Figure 3.3). 
 
 The cul1 strategy is thus the preferred option given a non-vaccination 
scenario and in the absence of antiviral agents. The total costs for cul1 are 
€87m higher compared to av1, and €132m higher compared to av1. 
 Figure 3.2 shows that both av1 and av2 have lower costs than cul1 over the 
whole domain of percentile values. The av2 strategy has lower costs than the 
av1 strategy. 
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Figure 3.2 Distribution of the outcomes: total cost for the cul1 strategy 
compared to the application of antiviral agents in a 1- or 2-km 
radius around infected farms, in million euros (excluding 
enforcement costs) 
 
 
 Results for the scenario where vaccination is considered a policy option or 
part of the contingency plan are presented in Figure 3.2. Because vac2_EU has 
€25m lower total costs compared to vac1_EU, vac2_EU is the benchmark to 
evaluate the economic effects of the strategies vac1_av1 and vac2_av2. 
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Figure 3.3 Distribution of the outcomes: comparison of vaccination 
strategies with or without the application of antiviral agents, 
in million euros (excluding enforcement costs) 
 
 
 Figure 3.3 shows that adding antiviral drugs to the vaccination strategy 
lowers the average total costs compared to vaccinating in the same radius 
without the use of antiviral agents (excluding the costs of these agents and 
their application). However, the average total costs for vac1_av1 are higher 
than for vac2_EU. 
 Compared to vac2_ EU, the costs of vac1_av1 are €14m higher. So, if 
antiviral agents are available, vac2_EU is still preferred over vac1_av1. 
However, extending the radius to 2 km, the total direct costs for vac2_av2 are 
€7m lower than for vac2_EU. 
 The ranking of the strategies based on their economic impact does not 
change for the whole range of potential outbreak outcomes since the lines of 
the presented results never cross as shown in Figures 2 and 3. 
 In a situation where there is no preference for eradication with or without 
vaccination, the vac2_av2 strategy is the most cost-effective strategy (under 
the condition of no costs for antiviral agents). 
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3.2 Application of antiviral agents: What is the 'price tolerance'? 
 
The numbers of doses needing treatment with antiviral agents differ 
substantially between the evaluated strategies (Table 3.3 and Figure 3.4). 
In strategies that include vaccination, only sows are treated whereas the av_1 
and av_2 strategies also include piglets and finishers. The numbers of doses 
differ substantially between the av_1 and av_2 strategy, whereas the variation 
between the two vaccination strategies vac1_av1 and vac2_av2 is much 
smaller. As shown in Figure 3.5a and Figure 3.5b, the number of doses used in 
an outbreak varies substantially also within a strategy. 
 
Table 3.3 Number of doses applied per strategy 
 
# doses 
Strategy Average 5% percentile 95% percentile 
vac1_av1 664,501 217,684 1,315,910 
vac2_av2 1,089,853 446,008 2,001,753 
av1 7,653,543 2,410,521 21,135,858 
av2 12,947,618 5,197,441 24,588,548 
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Figure 3.4 Number of doses of antiviral agents depending on the size of 
an outbreak 
 
 
 As previously stated, the total costs for the strategies exclude the price for 
antiviral agents or their application. The differences in costs between strategies 
with and without treatment are the maximum tolerated prices for the antiviral 
agents or their application to break even. Dividing this difference by the number 
of doses needed gives the maximum price per dose applied (Table 3.4). 
 
Table 3.4 Maximum price per dose 
Strategy Price per dose (euro) 
vac1_av1 vac2_av2 av1 av2 
EU 921 581 67 49 
cul1 158 116 10 10 
vac1_EU 15 29 -1 3 
vac2_EU -22 7 -4 1 
 
 When evaluating the maximum price per dose for the treatment with antiviral 
agents, the following two situations are of interest:1 
- A scenario in which vaccination is not considered a policy option with cul1 as 
reference strategy. 
                                                 
1 In the other situations a strategy without application of antiviral agents is the preferred policy option. For 
strategies without vaccination this is cul1 and for strategies with vaccination this is vac2_EU.  
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In this situation av2 is the preferred option (Table 3.2), since it has the 
lowest average total direct costs (excluding enforcement costs). Despite the 
large number animals to be treated and therefore the large number of doses 
which are needed, the maximum price per dose for av2 is €10. 
- A scenario in which vaccination is considered a viable policy option with 
vac2_EU as reference strategy. 
In this situation vac2_av2 is the strategy with the lowest average total cost 
(excluding enforcement costs) and the maximum price per dose for 
vac2_av2 is €7.1 
 
 To evaluate whether the maximum price per dose for antiviral drugs or for 
their application depends on the number of doses needed in a control strategy 
(hence defined as price elasticity), iterations were ranked according to the total 
outbreak costs. Subsequently, per iteration the maximum price per dose was 
calculated by comparing a treatment strategy with its benchmark strategy. 
The results are given in Table 3.5 and in Figure 3.5 for the comparison of the 
strategy av2 versus cul1 and in Figure 3.6 for the comparison of vac2_av2 
versus vac2_EU.  
 
Table 3.5 Price per dose: statistics and regression analysis 
Alternative Statistics Regression analysis a) 
Mean 5% 95% Constant B sig R2 
av2 (vs cul1) 10.41 5.74 15.49 11.4 7.4 E-8 0.00 0.025 
vac2_av2 (vs vac2_EU) 6.70 4.19 10.05 7.4 6.5*E-7 0.00 0.011 
a) Number of doses as independent variable. 
  
                                                 
1 As shown in the Appendix, in the case the enforcement costs are included in the calculations the maximum 
price per dose is €11/dose for av2 and €12/dose for vac2_av2 . 
  
31 
Figure 3.5a  (av2 versus cul1) Price per dose of antiviral agent related 
to the total direct costs of an outbreak. Strategies were 
ranked based on outbreak costs 
 
 
Figure 3.5b  (av2 versus cul1) Price per dose of antiviral agent related 
to the number of doses needed to control the outbreak. 
Strategies were ranked based on number of doses required 
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Figure 3.6a  (vac2_av2 versus vac2_EU) Price per dose of antiviral 
agent related to the number of doses needed to control 
the outbreak. Strategies were ranked based on number of 
doses required 
 
 
Figure 3.6b  (vac2_av2 versus vac2_EU) Price per dose of antiviral agent 
related to the number of doses needed to control the outbreak. 
Strategies were ranked based on number of doses required 
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 There is a large variation in the maximum price per dose (Table 3.5). 
A regression analysis was performed to obtain insight into the relation between 
total direct costs of the outbreak and the maximum price per dose. Although 
a significant relation was estimated, this relation was weak for both evaluated 
alternatives, as expressed by the small variance explained (R2) and the very 
small B-value. 
 
Conclusion 
There is large uncertainty in the maximum price per dose, although this variation 
only to a very small extent results from either the size of the outbreak or the 
number of doses of antiviral agents needed to control an outbreak. This variation 
is mainly caused by stochastic processes in the epidemiological model. 
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4 Discussion 
 
 
In this discussion the following issues will be addressed: the impact of 
enforcement costs on the maximum price per dose and export losses in relation 
to the control strategy. 
 
The impact of enforcement costs 
- Enforcement costs are mainly affected by the duration of the outbreak and 
not by the size of the outbreak. These costs can be substantial. In previous 
outbreaks enforcement costs were estimated to be as high as 335 k€ per 
day. However, these costs are heavily influenced by policy decisions on how 
extensive the enforcement effort should be. It is expected that in future 
outbreaks farmers' cooperation will increase, especially when a vaccination-
to-live strategy will be applied. Furthermore, cooperation will increase if the 
price of culled animals has been communicated beforehand, and transport 
of animals to slaughter houses is made possible after a relatively short 
period. So the incentives to move animals from infected to non-infected 
areas might decrease. The amount of enforcement measures and hence 
the costs per day may also decrease. 
- The impact of including or excluding enforcement costs on the maximum 
price of antiviral agents is more profound in alternative strategies in which 
these enforcement costs are a larger part of the total costs. When an 
outbreak is characterised by a relatively small number of culled farms as in 
those strategies that include vaccination (i.e. vac2_av2), the share of 
enforcement costs is larger. This results in a price difference of €5/dose 
(€12/dose versus €7/dose) for calculations including enforcement costs in 
the evaluation. In the strategies that involve large-scale preventive culling, 
the share of enforcement costs is relatively smaller; hence a smaller 
difference of €1/dose in the maximum price per dose is seen when 
enforcement costs are included in the calculations (€11/dose versus 
€10/dose). 
 
Export losses and costs related to trade restrictions 
- As a result of an epidemic, national and international market access for 
animals of susceptible species and their products is restricted. An epidemic 
of CSF will result in trade restrictions that are mostly related to the epidemic 
per se and do not depend on the specific characteristics of the control 
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strategy chosen. After the last outbreak it takes at least 6 weeks until the 
first movement restrictions are lifted. However, it can take up to 6 months 
until all trade restrictions in the EU are lifted and the 'normal' situation is 
resumed. Trade restrictions to third countries when applying a vaccination-
to-live strategy take 6 months to be lifted. 
- Total effects are determined by the size and duration of the outbreak, the 
control strategy applied and especially the country/area affected. For a 
country exporting mainly to third countries the present difference in export 
ban between a strategy with or without applying a vaccination-to-live strategy 
might be substantial. 
- Can the av2 strategy be an alternative for vac2_EU or vac2_av2? The 
maximum price per dose when comparing vac2_av2 with av2 is only €1 
(Table 3.4). So to make av2 a feasible alternative either the production price 
should be below €1/dose or the expected benefits from reduction in the 
duration of the export ban should be such that a higher price per dose 
is justified. 
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5 Conclusions 
 
 
The differences in total costs between eradication strategies with and without 
treatment with antiviral agents, in case the costs of antiviral agents are 
excluded from the calculations, are substantial. Implementing antiviral agents 
as part of the control strategies against CSF should be seriously considered. 
 Compared to the reference strategy of 1-km preventive culling the maximum 
price per dose (including application costs) is around €10 in case only treatment 
with antiviral agents in a 2-km radius around infected premises and no 
vaccination is applied as eradication strategy. In the case of a combination of 
vaccination (of finishers and piglets) and treatment with antiviral agents (of sows) 
in a 2-km radius around infected premises, this maximum price is about €7 per 
dose when 2-km emergency vaccination (of finishers and piglets) is taken as the 
reference strategy. A price per dose below the above values makes a control 
strategy with treatment of antiviral agents the preferred eradication strategy in the 
case of a CSF outbreak in a densely populated livestock area in the Netherlands. 
The maximum price per dose can be higher when export losses, ripple effects, 
spill-over effects and/or enforcement costs are also accounted for. 
 
- The maximum price per dose depends only to a limited extend on the size 
of an outbreak. However, there is substantial uncertainty which is mainly 
caused by variations stemming from the stochastic model used to estimate 
the epidemiological impact (Backer, 2011). 
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Appendix 1 
Huidige strategie bestrijding KVP in Nederland 
 
 
Uitgangspunten 
Uitgangspunt in de draaiboeken KVP is dat er in een cirkel van 2 km rondom 
besmette bedrijven gevaccineerd gaat worden. 
 Op varkensbedrijven worden op de bedrijven die in de vaccinatiecirkel liggen 
alle dieren behalve de dieren die drachtig kunnen zijn gevaccineerd. Het betreft 
vleesvarkens, fokberen, opfokzeugen en zuigende en gespeende biggen. 
De zeugen worden bij KVP niet gevaccineerd. Een bedrijf wordt in principe maar 
één keer gevaccineerd. Indien een bedrijf meerdere keren in een vaccinatie-
cirkel komt te liggen worden alleen nieuwe/pasgeboren dieren die nog niet 
gevaccineerd waren gevaccineerd. 
 
Maatregelen tijdens de uitbraak 
In de gebieden rondom uitbraken gelden onder andere restricties voor vervoer 
van en naar locaties met gevoelige dieren en wordt ook ander vervoer van 
agrarische voertuigen zoveel mogelijk beperkt. Zodra een besmetting is 
bevestigd zullen de maatregelen die in de EU-richtlijn genoemd zijn uitgevoerd 
worden. Dit betekent het ruimen van het besmette bedrijf, maar ook het instellen 
van een beschermingsgebied met een straal van ten minste 3 km om het 
besmette bedrijf. Daarnaast wordt een toezichtsgebied met een straal van ten 
minste 10 km om het besmette bedrijf ingesteld. Indien besloten wordt om te 
gaan vaccineren zal er een vaccinatiegebied ingesteld worden. In het vaccinatie-
gebied zijn, op basis van de richtlijn, dezelfde maatregelen van toepassing als in 
het beschermingsgebied en toezichtsgebied. 
 In de draaiboeken worden drie zogenaamde fases onderscheiden. De maat-
regelen die voor het vaccinatiegebied in aanvang van kracht zullen zijn (fase 1: 
geldt van het begin van vaccinatie tot 30 dagen na de laatste vaccinatie), zijn 
identiek aan het maatregelpakket van het beschermingsgebied en toezichts-
gebied. In de afbouw van de maatregelen worden de maatregelen van fasen 2 
en 3 van kracht. Fase 2 gaat in na fase 1 en is geldig tot een gunstige uitslag 
van de screening bekend is, fase 3 gaat in na de screening en is geldig tot 
Nederland door de EU vrij wordt verklaard. 
 De maatregelen in fase 2 zijn gelijk aan de maatregelen in fase 1: vatbare 
dieren mogen met een ontheffing vervoerd worden rechtstreeks naar een 
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slachthuis binnen of buiten het vaccinatiegebied. In fase 3 is het vervoer van 
vatbare dieren, met ontheffing, toegestaan tussen bedrijven binnen het vaccinatie-
gebied. Het vervoer van vatbare dieren naar een locatie buiten het vaccinatie-
gebied is verboden, tenzij de dieren met ontheffing rechtstreeks naar een 
slachthuis gaan. 
 Samenvattend: gedurende de uitbraakperiode (fase 1 tot en met fase 3) is 
er sprake van kanalisatie in zowel het vaccinatiegebied, beschermingsgebied 
en toezichtsgebied van alle gevoelige dieren en hun producten uit het gebied 
(figuur A.1). Kanalisatie houdt in dat de producten afzonderlijk herkenbaar 
bewerkt en separaat opgeslagen moeten worden (separaat opslaan zal naar 
verwachting zulke grote consequenties hebben dat VWA heeft aangegeven dat 
duidelijke identificatie voldoende is). 
 
Maatregelen na de uitbraak 
Ook na de uitbraak gelden er nog steeds beperkingen voor de afzet van gevac-
cineerde dieren en hun producten. De duur van deze periode met beperking na 
de uitbraak is afhankelijk van de dierziekte. De interpretatie van de richtlijnen is 
hieronder weergegeven1 (Persoonlijke Mededeling: Akkerman, 2009). 
 Voor KVP geldt dat hier onderscheid gemaakt wordt tussen gebruik van 
levend en marker vaccin. Bij levend vaccin geldt dat het vlees gedurende 
6 maanden (na laatste vaccinatie) een hittebehandeling moet ondergaan. 
Bij gebruik van een marker vaccin (art 19 lid 9 Richtlijn 2001/89/EG) gelden 
andere procedures. In art 19 lid 8 9 Richtlijn 2001/89/EG staat vermeld dat, 
in afwijking van lid 5 en 6, de maatregelen zoals genoemd in art 4 kunnen 
worden ingetrokken onder genoemde voorwaarden. Door dit laatste artikel 
kan de periode van 6 maanden worden verkort. 
 Bij vaccinatie tegen KVP worden op de vermeerderingsbedrijven in de 
vaccinatiegebieden de aanwezige biggen met markervaccin gevaccineerd 
(en de zeugen niet dit in tegenstelling tot MKZ). De tijdshorizon met beperkingen 
voor afzet van producten van gevaccineerde dieren is begrensd tot de levens-
duur van de gevaccineerde dieren. Er zijn maar een relatief korte tijd gevacci-
neerde dieren op het bedrijf aanwezig. Na ongeveer 70 dagen (de gemiddelde 
afleverleeftijd van een big naar het vleesvarkenbedrijf) na de laatste vaccinatie 
                                                 
1 Eén van de speerpunten binnen het EU project 'Animal Health Strategy' betreft de herziening van de 
wetgeving met betrekking tot dierziektebestrijding. Hierbij zal zeker de mogelijkheid van vaccinatie als 
bestrijdingsinstrument, maatregelen tijdens vaccinatie, vermarkten van producten en vlees van 
gevaccineerde dieren herzien worden (meer gericht op de praktijk). 
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zullen, bij afwezigheid van verdere vervoersbeperkingen, geen gevaccineerde 
dieren meer op het zeugenbedrijf aanwezig zijn. Op een vleesvarkensbedrijf 
worden in de vaccinatiegebieden alle aanwezige dieren eenmalig gevaccineerd. 
Dit betekent dat binnen ongeveer drie maanden deze dieren aan het slachthuis 
geleverd zullen zijn. De maximale duur met beperkingen is dus circa een half jaar 
(duur van big tot met aflevering vleesvarken). 
 
Figuur A1.1 Bestrijdingsstrategie/restricties per gebied gedurende en 
na een MKZ-/KVP-uitbraak 
 
 
  
2 km
Infectiegebied
10 km
Uitbraakperiode
t/m 28 dagen na laatste infectie
Na uitbraakperiode
MKZ: runderen 6 maanden na vaccinatie
MKZ: varkens 3 maanden na vaccinatie
KVP: 6 maanden na vaccinatie
Vaccinatiegebied Toezichtsgebied
Type gebied:
Ruimen
Bestrijdingsstrategie / restricties:
Kanalisatie Geen restricties
Beschermingsgebied
3 km
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Appendix 2 
Enforcement costs 
 
 
Table A2.1  Enforcement costs (price level 2012) 
RDW 2,907 €/day 
Army 41,281 €/day 
Customs 17,443 €/day 
Police 204,081 €/day 
Agricultural inspection (AID) 69,771 €/day 
Enforcement (total) 335,484 €/day 
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Appendix 3 
Tables with results for enforcement costs INCLUDED 
 
 
Table A3.1 Costs of the different control strategies in the case of an 
outbreak of CSF in a DPLA in the Netherlands, in million euros 
(including enforcement costs) 
 Total costs (in million €) 
Mean  ( 5% 95% ) 
EU 949 195 1574 
cul1 254 105 465 
vac1_EU 168 80 286 
vac1_av11 151 74 260 
vac2_EU 117 65 187 
vac2_av2* 105 60 164 
av1* 190 76 438 
av2* 110 60 196 
a) The cost of the antiviral agents are not included in this calculation. 
 
Table A3.2 Differences in average total direct costs of different control 
strategies in the case of an outbreak of CSF in a DPLA in the 
Netherlands, in million euros (including enforcement costs) 
 EU cul1 vac1_EU vac1_av1 vac2_EU vac2_av2 av1 av2 
EU         
cul1 -695        
vac1_EU -780 -86       
vac1_av1 -798 -103 -18      
vac2_EU -831 -137 -51 -33     
vac2_av2 -844 -149 -64 -46 -13    
av1 -759 -64 21 39 72 85   
av2 -839 -144 -59 -41 -8 5 -80  
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Table A3.3 Maximum price per dose, based on total costs (including 
enforcement costs) 
Strategy Price per dose 
vac1_av1 vac2_EU vac2_av2 av1 av2 
EU 1201  775 85 65 
cul1 156  137 7 11 
vac1_EU 27  59 -2 5 
vac1_av1 0 50 42 -4 3 
vac2_EU  0 12 -8 1 
vac2_av2   0 -10 -0.40 
av1    0 6 
av2     0 
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